Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 151-154

  Liu, Zhaoxu ^a,b   Marquez, Marcela ^a   Nilsson, Sten ^a   Holmberg, Anders R ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANDONG UNIVERSITY   (China)

Author keywords

LNCaP; Prostate cancer; Somatostatin; Somatostatin receptors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; COMPLEMENTARY DNA; HISTONE; MESSENGER RNA; SOMADEX; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 5; TRICHOSTATIN A; UNCLASSIFIED DRUG; AZACITIDINE; DRUG DERIVATIVE; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DNA METHYLATION; DRUG EXPOSURE; EPIGENETICS; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; MALE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; UPREGULATION;

AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; RNA, MESSENGER; SOMATOSTATIN; UP-REGULATION;

EID: 49849105127     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.151     Document Type: Article

References (22)

1. Joensuu TK, Nilsson S, Holmberg AR, Marquez M, Tenhunen M, Saarto T and Joensuu H: Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer. Ann NY Acad Sci 1028: 361-374, 2004.
2. Liu Y: Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions. Cancer Lett 239: 21-26, 2006.
3. Moller LN, Stidsen CE, Hartmann B and Holst JJ: Somatostatin receptors. Biochim Biophys Acta 1616: 1-84, 2003.
4. Olias G, Viollet C, Kusserow H, Epelbaum J and Meyerhof W: Regulation and function of somatostatin receptors. J Neurochem 89: 1057-1091, 2004.
5. Tatoud R, Degeorges A, Prevost G, Hoepffner JL, Gauville C, Millot G, Thomas F and Calvo F: Somatostatin receptors in prostate tissues and derived cell cultures, and the in vitro growth inhibitory effect of BIM-23014 analog. Mol Cell Endocrinol 113: 195-204, 1995.
6. Dasgupta P: Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 102: 61-85, 2004.
7. Dizeyi N, Konrad L, Bjartell A, Wu H, Gadaleanu V, Hansson J, Helboe L and Abrahamsson PA: Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol 7: 91-98, 2002.
8. Gonzalez-Barcena D, Schally AV, Vadillo-Buenfil M, Cortez-Morales A, Hernandez LV, Cardenas-Cornejo I and Comaru-Schally AM: Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse. Prostate 56: 183-191, 2003.
9. Sinisi AA, Rossi V, Prezioso D, Notaro A, Bellastella G, Panza N, Bellastella A and Pasquali D: The role of somatostatin analogs in the management of prostate cancer. J Endocrinol Invest 26: 120-124, 2003.
10. Reubi JC: Somatostatin and other Peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80: 51-56, 2004.
11. Fang X, Zheng C, Liu Z, Ekman P and Xu D: Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2′-deoxycytidine. Oncol Rep 12: 523-526, 2004.
12. Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD and degli Uberti EC: Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab 86: 2161-2169, 2001.
13. Halmos G, Schally AV, Sun B, Davis R, Bostwick DG and Plonowski A: High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab 85: 2564-2571, 2000.
14. Hansson J, Bjartell A, Gadaleanu V, Dizeyi N and Abrahamsson PA: Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate 53: 50-59, 2002.
15. Das PM and Singal R: DNA methylation and cancer. J Clin Oncol 22: 4632-4642, 2004.
16. Gilbert J, Gore SD, Herman JG and Carducci MA: The clinical application of targeting cancer through histone acetylation and hypomethylation. Clin Cancer Res 10: 4589-4596, 2004.
17. Hess-Stumpp H: Histone deacetylase inhibitors and cancer: from cell biology to the clinic. Eur J Cell Biol 84: 109-121, 2005.
18. Li LC, Carroll PR and Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 97: 103-115, 2005.
19. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, Suzuki H, Ito H, Tsukino H, Katoh T, Sugimura Y and Shiraishi T: Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 106: 382-387, 2003.
20. Esteller M: DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 17: 55-60, 2005.
21. Letsch M, Schally AV, Szepeshazi K, Halmos G and Nagy A: Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238. J Urol 171: 911-915, 2004.
22. Minuto F, Ferone D, Arvigo M and Barreca A: Rationale for treating cancer with somatostatin analogs. J Endocrinol Invest 26: 117-119, 2003.